Novamind Inc., a company specializing in psychedelic medicine, announced it will conduct a phase 2 clinical trial examining psilocybin for major depressive disorder.
The first patient has completed random assignment in the study.
“The Psilocybin Trial is a key step in moving psilocybin through the clinical development process and closer to regulatory approval,” Paul Thielking, MD, chief scientific officer at Novamind, said in a press release. “Today marks another exciting milestone for our team as we continue to support drug developers, not-for-profits and academic